Rebyota, a fecal microbiota product, is used to prevent the recurrence of Clostridioides difficile infection (CDI).

Enterprise Therapeutics has today revealed that the first participant with cystic fibrosis has been administered a dose in its Phase 2a study of ETD001.

Etranacogene dezaparvovec, marketed under the brand name Hemgenix, is a gene therapy used to treat adults with Hemophilia B.

Merck Reveals Preliminary Findings from Phase 2b/3 Study of Clesrovimab (MK-1654), an Experimental Monoclonal Antibody for RSV Prevention in Infants.

Teplizumab, marketed under the brand name Tzield, was approved by the FDA on November 17, 2022.

FDA Greenlights Samsung Bioepis' EPYSQLI® (eculizumab-aagh) as a Biosimilar to Soliris (eculizumab).

Mirvetuximab soravtansine, marketed under the brand name Elahere, is approved by the FDA for the treatment of adults with ovarian cancer.

Zymeworks Receives FDA Approval for ZW191 Investigational New Drug Application, a Cutting-Edge Folate Receptor-⍺ Targeted Topoisomerase I Inhibitor Antibody-Drug Conjugate.

Tremelimumab (brand name: Imjudo) is indeed FDA-approved. It is a monoclonal antibody that belongs to the class of drugs known as anti-CTLA-4 monoclonal antibodies.

Jul 25th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Futibatinib (brand name: Lytgobi) is an FDA-approved medication used to treat certain types of bile duct cancer (cholangiocarcinoma).

STADA and Alvotech introduce Uzpruvo, the initial ustekinumab biosimilar approved against Stelara, in Europe.